

# 1 **Reactive vaccination of workplaces and schools against COVID-19**

2 Benjamin Faucher<sup>1</sup>, Rania Assab<sup>1</sup>, Jonathan Roux<sup>2</sup>, Daniel Levy-Bruhl<sup>3</sup>, Cécile Tran Kiem<sup>4,5</sup>,  
3 Simon Cauchemez<sup>4</sup>, Laura Zanetti<sup>6</sup>, Vittoria Colizza<sup>1</sup>, Pierre-Yves Boëlle<sup>1</sup>, Chiara Poletto<sup>1</sup>

4 <sup>1</sup>INSERM, Sorbonne Université, Pierre Louis Institute of Epidemiology and Public Health, Paris, France

5 <sup>2</sup>Univ Rennes, EHESP, REPERES « Recherche en Pharmaco-Epidémiologie et Recours aux Soins » – EA 7449,  
6 15 avenue du Professeur-Léon-Bernard, CS 74312, 35043 Rennes, France

7 <sup>3</sup>Santé Publique France, Saint Maurice, France

8 <sup>4</sup>Mathematical Modelling of Infectious Diseases Unit, Institut Pasteur, UMR2000, CNRS, Paris, France

9 <sup>5</sup>Collège Doctoral, Sorbonne Université, Paris, France

10 <sup>6</sup>Haute Autorité de Santé, Saint-Denis, France

11

12 Corresponding author: Chiara Poletto ([chiara.poletto@inserm.fr](mailto:chiara.poletto@inserm.fr))

13

14

15

## 16 **Abstract**

17 As vaccination against COVID-19 stalls in some countries, increased accessibility and more  
18 adaptive approaches may be useful to keep the epidemic under control. Here we study the  
19 impact of reactive vaccination targeting schools and workplaces where cases have been  
20 detected, with an agent-based model accounting for COVID-19 natural history, vaccine  
21 characteristics, individuals' demography and behaviour and social distancing. We study  
22 epidemic scenarios ranging from sustained spread to flare-up of cases, and we consider  
23 reactive vaccination alone and in combination with mass vaccination. With the same number  
24 of doses, reactive vaccination reduces cases more than non-reactive approaches, but may  
25 require concentrating a high number of doses over a short time in case of sustained spread.  
26 In case of flare-ups, quick implementation of reactive vaccination supported by enhanced  
27 test-trace-isolate practices would limit further spread. These results provide key information to  
28 promote an adaptive vaccination plan in the months to come.

29

## 30 Introduction

31 Achieving high vaccination coverage against COVID-19 is now the main strategy to reduce  
32 disease burden and pressure on health care organisations and to lift non-pharmaceutical  
33 interventions (NPI). To this end, mass vaccination campaigns started in Western countries  
34 mainly prioritising health care workers and groups more at risk of severe infection <sup>1-4</sup> – i.e. the  
35 elderly and those with comorbidities. However, now that vaccination has been opened to all  
36 adults, vaccine uptake remains below needs - e.g. in France, the United States - due to  
37 logistical issues, vaccine accessibility and/or hesitancy. With cases on the rise again due to  
38 the emergence of new viral variants, vaccine delivery must become more adaptive in  
39 response to the epidemic situation. For instance, it could preferentially target people at  
40 higher risk of infection, e.g. because attending places where more cases are reported. As  
41 people who are hesitant to vaccinate are more likely to accept vaccination when the  
42 perceived risk of infection is higher <sup>5</sup>, this would help overcome barriers to vaccination <sup>6</sup>.

43 Hotspot vaccination, which involves redirecting vaccine supplies to geographic areas of  
44 highest incidence, is already part of some European countries' plans to combat the  
45 emergence of variant Delta <sup>6</sup>. But other reactive vaccination schemes are possible, such as  
46 ring vaccination that targets contacts of confirmed cases or contacts of those contacts, or  
47 vaccination in workplaces or schools where cases have been detected. This could potentially  
48 improve vaccine impact by preventing transmission where it is active and even enable the  
49 efficient management of flare-ups. For outbreaks of smallpox or Ebola fever, ring vaccination  
50 has proved effective to rapidly curtail the spread of cases <sup>7-10</sup>. However, the experience of  
51 these past epidemics cannot be transposed directly to COVID-19 due to the many differences  
52 in the infection characteristics and epidemiological context. For example, COVID-19 cases  
53 are infectious a few days before symptom onset <sup>11</sup>, but generally detected a few days later.  
54 This means they may have had time to infect their direct contacts, potentially limiting the  
55 efficacy of ring vaccination. Vaccinating an extended network of contacts, as could be done  
56 with the vaccination of whole workplaces or schools, could have a larger impact, especially if  
57 adopted in combination with strengthened protective measures to slow down transmission,  
58 such as masks, physical distancing, and contact tracing. This could be feasible in many  
59 countries, leveraging the established test-trace-isolate (TTI) system that enables prompt  
60 detection of clusters of cases to inform where vaccines should be deployed. Properly  
61 assessing the interest of reactive vaccination therefore requires to consider in detail the  
62 interactions of vaccine characteristics, pace of vaccination, COVID-19 natural history, case  
63 detection practices and overall changes in human contact behaviour.


64 We therefore extend an agent-based model that has been previously described<sup>12</sup> to quantify  
65 the impact of a reactive vaccination strategy targeting workplaces, universities and 18+ years  
66 old in high schools where cases have been detected. We compare the impact of reactive  
67 vaccination with non-reactive vaccination in similar settings or with mass vaccination, and test  
68 these strategies alone and in combination. We explore differences in vaccine availability and  
69 logistic constraints, and assess the influence of the dynamic of the epidemic (low/high  
70 incidence, new emerging variant) and different stages of the vaccination campaign.

## 71 **Results**

### 72 **COVID-19 vaccination strategies targeting workplaces and schools**

73 We extend a previously described SARS-CoV-2 transmission model<sup>12</sup> to simulate vaccine  
74 administration, running in parallel with other interventions - i.e. contact tracing, telework and  
75 social restrictions. Following similar approaches<sup>13-16</sup>, the model is stochastic and individual  
76 based. It takes as input a synthetic population reproducing demographic, social-contact  
77 information, workplace sizes and school types (Figure 1A) of a typical medium-sized French  
78 town (117,492 inhabitants). Contacts are described as a dynamic multi-layer network<sup>12</sup>  
79 (Figure 1B).

80 We assume that the vaccine reduced susceptibility, quantified by the vaccine efficacy  $VE_S$ ,  
81 and symptomatic illness after infection, quantified by  $VE_{SP}$ <sup>17</sup> (Figure 1C). The vaccine-  
82 induced protection is described based on the characteristics of mRNA vaccines<sup>18,19</sup> with no  
83 protection up to 1 week after inoculation, intermediate protection after 1 week ( $VE_{S,1} = 52\%$   
84 and  $VE_{SP,1} = 62\%$ ), and maximum protection after 2 weeks ( $VE_{S,2} = 87\%$  and  $VE_{SP,2} =$   
85  $90\%$ ).



86

87 **Figure 1. A** Distribution of workplace size and of school type for the municipality of Metz (Grand East region,  
 88 France), used in the simulation study. **B** Schematic representation of the population structure, the reactive  
 89 vaccination and contact tracing. The synthetic population is represented as a dynamic multi-layer network, where  
 90 layers encode contacts in household, workplace, school, community and transport. In the figure, school and  
 91 workplace layers are collapsed and community and transport are not displayed for the sake of visualisation. Nodes  
 92 repeatedly appear on both the household and the workplace/school layer. The identification of an infectious  
 93 individual (in purple in the figure) triggers the detection and isolation of his/her contacts (nodes with orange border)  
 94 and the vaccination of individuals attending the same workplace/school and belonging to the same household who  
 95 accept to be vaccinated (green). **C** Compartmental model of COVID-19 transmission and vaccination. Description  
 96 of the compartments is reported on the Methods section. **D** Timeline of events following infection for a case that is  
 97 detected in a scenario with reactive vaccination. For panels C, D transition rate parameters and their values are  
 98 described in the Methods and in the Supplementary Information.

99 To parametrise the epidemiological context, we assume 26%<sup>20,21</sup> of the population was fully  
 100 immune to the virus and the reproductive ratio is  $R = 1.2$ , in the range of values estimated  
 101 during the ascending phase of winter 20-21/spring 2021 epidemic waves<sup>22</sup>. We model the  
 102 baseline TTI policy after the French situation, allowing 3.6 days on average from symptoms

103 onset to detection and 2.8 average contacts detected and isolated per index case<sup>23</sup> (Figure 1  
104 D). We assume that 50% of clinical cases and 10% of subclinical cases are detected.  
105 Scenarios with enhanced TTI are described later in the text.


106 We then model vaccination of 18+ years old population assuming vaccination uptake is  
107 bounded above by vaccine acceptance, set to 66% in the 18-65 years old and 90% in the  
108 over 65 years old at baseline, based on surveys conducted on the French population<sup>24</sup>.  
109 When the vaccine is proposed in the context of reactive vaccination, we also consider uptake  
110 up to 100%. We model a *reactive vaccination* strategy, where the detection of a case thanks  
111 to TTI triggers the vaccination of household members and those in the same workplace or  
112 school (Figure 1D). In this scenario, a delay of 2 days on average is assumed between the  
113 detection of the case and vaccination to account for logistical issues - i.e. ~5.6 days on  
114 average from the index case's symptoms onset. We also model three *non-reactive*  
115 vaccination strategies, i.e. i) where vaccination is deployed randomly throughout the mass  
116 vaccination program (*mass*) or ii) in school sites (*school location*) or iii)  
117 workplaces/universities (*workplaces/universities*) chosen at random, up to the maximum  
118 number of doses available daily. In the school location vaccination, we assume vaccine sites  
119 are created in relation with schools to vaccinate pupils and their household members who are  
120 above 18 years old. The impact of these strategies is evaluated based on the comparison  
121 with a reference scenario, where no vaccination campaign is conducted during the course of  
122 the simulation and vaccination coverage remains at its initial level.

### 123 **Comparison between reactive and non-reactive vaccination strategies**

124 In Figure 2 we compare all strategies, assuming that vaccine uptake is the same in reactive  
125 and non-reactive vaccination as reference, and initial vaccination coverage among adults is  
126 small, i.e. 13% of the [18,60] group. During the course of the simulation we consider daily  
127 first-dose vaccination rates for non-reactive strategies between 85 first doses per 100,000  
128 inhabitants (corresponding to the initial vaccination capacity in France in January/February  
129 2021) and 512 first doses per 100,000 inhabitants (close to highest vaccination capacity  
130 values reached in May/June 2021 before it declined in June). Panels A-C show the results for  
131 a *high incidence* scenario, here defined by initial incidence at ~160 clinical cases weekly per  
132 100,000 inhabitants - close to values registered during the first half of May 2021 in France.  
133 Panel A shows the relative reduction in the attack rate after two months as a function of the  
134 number of first daily doses, while Figure 2B compares the incidence profiles under different  
135 strategies at a similar number of vaccine doses. The mass, school location and  
136 workplaces/universities strategies have a similar impact on the epidemic. They lead to a  
137 reduction between 3.6% and 4.9% of the attack rate, when 85 first doses per 100,000

138 inhabitants are administered each day, and between 20% and 22% with 511 per 100,000  
 139 inhabitants. Among the three, mass vaccination has the lowest impact. This is because the  
 140 workplaces/universities and school location strategies target a portion of the population with  
 141 more contacts - working population, or population living in large households - with a greater  
 142 potential to transmit the infection. Compared with each of the three strategies, reactive  
 143 vaccination produces a stronger reduction in cases at equal number of doses in the two-  
 144 month period, i.e. a reduction of 24.5% with the number of first-dose vaccinations being 247  
 145 per 100,000 inhabitants each day on average.

146 In panel C we show the number of first doses in time and the number of places to vaccinate -  
 147 as a proxy to the incurred costs of vaccine deployment. The number of daily inoculated doses  
 148 is initially high, with 1112 doses per 100,000 inhabitants used in a day at the peak of vaccine  
 149 demand, but declines rapidly afterwards down to 86 doses. More than 10 workplaces/schools  
 150 (0.3% of workplaces and eligible schools of the municipality considered) would need to be  
 151 vaccinated each day at the peak of vaccine demand.



152  
 153 Figure 2. **A-D** High incidence scenario, with initial weekly incidence of clinical cases ~160 per 100,000  
 154 inhabitants. **A** Relative reduction (RR) in the attack rate (AR) over the first two months for all strategies as a  
 155 function of the vaccination pace. RR is computed as  $(AR_{ref} - AR)/AR_{ref}$  where  $AR_{ref}$  is the AR of the reference  
 156 scenario, with initial vaccination only. AR is computed from clinical cases. **B** Incidence of clinical cases with  
 157 different vaccination strategies. The grey curve indicates the reference scenario. The non-reactive scenarios  
 158 plotted are obtained with 255 new daily vaccinations per 100,000 inhabitants. In the reactive vaccination the  
 159 average pace is 247 new daily vaccinations per 100,000 inhabitants. **C** Number of daily first-dose vaccinations,  
 160 and workplaces/schools (WP/S in the plot) where vaccines are deployed. **D-F** Same as A-C for the low incidence

161 scenario with initial incidence of clinical cases 5 per 100,000 inhabitants. In panel E, the vaccination pace is 85  
162 and 46 daily first-dose vaccinations per 100,000 inhabitants for the non-reactive and reactive strategies,  
163 respectively. In all cases we assumed the following parameters:  $R=1.2$ ; Initial immunity 26%; vaccinated at the  
164 beginning 81% and 13% for 60+ and <60, respectively; 20% of individuals are doing teleworking and 30% of  
165 community contacts are removed. Values are means over 2000 stochastic simulations, error bars in panels A and  
166 D are derived from the standard errors of the AR. Error bars in panels B, C, E, F, are not displayed for the sake of  
167 visualisation.

168 In Figure 2 D-F we consider a *low incidence* scenario, i.e. 5 clinical cases weekly per 100,000  
169 inhabitants. In this scenario, reactive vaccination yields a relative reduction in the attack rate  
170 that is twice the one produced by the workplaces/universities strategy with 85 daily doses per  
171 100,000 inhabitants, but only using 46 daily doses per 100,000 on average in the two-months  
172 period. The deployment of vaccines and the number of workplaces/schools to vaccinate is  
173 initially low and increases gradually with incidence.

174 We have considered so far specific scenarios in terms of epidemiological and vaccine  
175 parameters. In the Supplementary Information we explore alternative values of key  
176 parameters, e.g. initial incidence, transmission, immunity level of the population, fraction of  
177 adults initially vaccinated, reduction in contacts due to social distancing, vaccine efficacy and  
178 time needed for the vaccine to become effective. In particular, we explore a reduction in  
179 vaccine efficacy of 30% and a longer time needed for the vaccine protection to mount -  
180 parameterized according to <sup>25</sup>. In varying these parameters, the overall effectiveness of  
181 vaccination, regardless of the strategy, changes. However, reactive vaccination remains in all  
182 cases the most effective strategy when the comparison is done at equal number of doses. We  
183 also tested the robustness of our results according to the selected health outcome, using  
184 hospitalisations, ICU admissions, ICU bed occupancy, deaths, life-years lost and quality-  
185 adjusted life-years lost, finding the same qualitative behaviour.

## 186 **Combined reactive and mass vaccination for managing sustained COVID-19** 187 **spread**


188 With high availability of vaccine doses, reactive vaccination could be deployed on top of mass  
189 vaccination. We consider first the high incidence scenario defined in the previous section and  
190 compare mass and reactive vaccination simultaneously (*combined strategy*) with mass  
191 vaccination alone. We focus on the first two months since the implementation of the  
192 vaccination strategy. At an equal number of doses within the period, the combined strategy  
193 outperforms mass vaccination in reducing the attack rate. For instance, the relative reduction  
194 in the attack rate would go from 18%, when 448 daily doses per 100,000 inhabitants are

195 deployed for mass vaccination, to 29%, when the same number of doses are used for  
196 reactive and mass vaccination combined (Figure 3A).

197 We explore alternative scenarios where the number of vaccines used and places vaccinated  
198 are limited due to availability and logistic constraints. We assess the effect of three  
199 parameters: (i) the maximum daily number of vaccines that can be allocated towards reactive  
200 vaccination (with caps going from 85 to 512 per 100,000 inhabitants, compared with unlimited  
201 vaccine availability assumed in the baseline scenario), (ii) the time from the detection of a  
202 case and the vaccine deployment (set to 2 days in the baseline scenario, and here explored  
203 between 1 and 4 days), and (iii) the number of detected cases that triggers vaccination in a  
204 place (from 2 to 5 cases, vs. the baseline value of 1). The number of first-dose vaccinations in  
205 time under the different caps is plotted in Figure 3B. A small cap on the number of doses  
206 limits the impact of the reactive strategy. Figure 3C shows that the attack rate relative  
207 reduction drops from 21% to 8.2% if only a maximum of 85 first doses per 100,000  
208 inhabitants daily can be used in reactive vaccination. However, the inclusion of reactive  
209 vaccination is beneficial (i.e. RR is above the mass strategy only with a similar number of  
210 doses) as soon as the cap in the number of doses is higher than 85 per 100,000 inhabitants.  
211 Doubling the time required to start reactive vaccination, from 2 days to 4 days, has a limited  
212 effect on the reduction of the AR (relative reduction reduced from 29% to 27%, Figure 3D).  
213 Increasing the number of detected cases used to trigger vaccination to 2 (respectively 5)  
214 reduces the relative reduction to 22% (respectively 15%) (Figure 3E).

215 We so far assumed that vaccine uptake is the same in mass and reactive vaccination. In  
216 Figure 3F we consider a scenario where vaccine uptake with reactive vaccination climbs to  
217 100%. Attack rate relative reduction increases in this case from 29% to 37%, with a demand  
218 of 604 daily doses per 100,000 inhabitants on average.

219



220


221 Figure 3. **A** Relative reduction (RR) in the attack rate (AR) over the first two months for the combined strategy  
 222 (mass + reactive) and the mass strategy with the same number of first-dose vaccinations as in the combined  
 223 strategy during the period. RR is computed with respect to the reference scenario with initial vaccination only, as in  
 224 Figure 2. Combined strategy is obtained by running in parallel the mass strategy - with 81, 170, and 255 daily  
 225 vaccination rate per 100,000 inhabitants - and the reactive strategy. Number of doses displayed in the x-axis of the  
 226 figure is the total number of doses used by the combined strategy. Corresponding incidence curves are reported in  
 227 Figure S6 of Supplementary Information. **B** Number of first-dose vaccinations deployed each day for the  
 228 combined strategy with different daily vaccines' capacity limits. **C, D, E** AR RR for the combined strategy as a  
 229 function of the average daily number of first-dose vaccinations in the two-month period. Symbols of different  
 230 colours indicate: (**C**) different values of daily vaccines' capacity limit; (**D**) different time from case detection to  
 231 vaccine deployment; (**E**) different threshold size for the cluster to trigger vaccination. In panel C and E the curve  
 232 corresponding to mass vaccination (the same one as in panel A) is also plotted as a guide to the eye. **F**  
 233 Comparison between 100% and baseline vaccination uptake in case of reactive vaccination. In all cases we  
 234 assumed the following parameters:  $R=1.2$ ; Initial immunity 26%; vaccinated at the beginning 81% and 13% for 60+  
 235 and <60, respectively; 20% of individuals are doing teleworking and 30% of community contacts are removed.  
 236 Values are means over 2000 stochastic simulations, error bars are derived from the standard errors of the AR.

### 237 **Combined reactive and mass vaccination for managing a COVID-19 flare-up**

238 We then quantify the impact of reactive vaccination on the management of a flare-up of  
 239 cases, as possibly implemented upon detection of a new viral variant in the territory. We  
 240 consider here a higher vaccination coverage among adults at the beginning (i.e. 33% of  
 241 [18,60]) and no teleworking and social restrictions, similarly to what was observed in June

242 2021. A mass vaccination campaign with 512 first doses per day per 100,000 inhabitants is  
 243 underway from the start and baseline TTI is in place prior to cases' introduction. To start a  
 244 simulation, three infectious individuals are introduced in the population where the virus variant  
 245 is not currently circulating. Upon detection of the first case, we assume that TTI is enhanced,  
 246 finding 100% of clinical cases, 50% of subclinical cases and three times more contacts  
 247 outside the household with 100% compliance to isolation (Table S4 of the Supplementary  
 248 Information) - the scenario without TTI enhancement is also explored for comparison. As  
 249 soon as the number of detected cases reaches a predefined threshold, reactive vaccination is  
 250 started on top of the mass vaccination campaign. We assume vaccine uptake increases to  
 251 100% for reactive vaccination but stays at its baseline value for other approaches. In Figure  
 252 4A, B, C we quantify the probability of extinction and the average attack rate. We compare  
 253 the combined scenario with mass vaccination alone at an equal number of doses, and we  
 254 investigate starting the reactive vaccination after 1, 5 or 10 detected cases.

255 With enhanced TTI and 100% uptake for reactive vaccination starting from the first detected  
 256 case, the probability of extinction would increase (from 0.41 to 0.45) and the attack rate  
 257 decrease (from 41 to 34 cases per 100 000 inhabitants), compared with the mass scenario.  
 258 The added value of reactive vaccination would decrease if more detected cases are required  
 259 to start the intervention. We consider a similar level of uptake for reactive vaccination and  
 260 mass vaccination, finding no advantage of reactive vaccination in this case. Assuming no  
 261 enhancement in TTI occurs after the detection of the first case, we find no effect of the  
 262 reactive vaccination in disease containment, irrespective of the level of vaccination uptake.  
 263 Instead, the effect of the strategy on the reduction in attack rate is qualitatively similar to the  
 264 enhanced TTI case.



265  
 266 Figure 4 A Probability of extinction for an outbreak starting with three cases according to the measure  
 267 implemented. Four vaccination strategies are compared: mass only, combined where the reactive vaccination  
 268 starts at the detection of 1, 5, 10 cases (Combined cl. size= 1, 5, 10 in the figure). Four scenarios are compared,  
 269 considering both baseline and 100% uptake for reactive vaccination, and both baseline and enhanced TTI after  
 270 the detection of the first case. Probability of extinction is computed from the fraction of runs for which the epidemic

271 reaches extinction (no active infections) within the first two months after the first detected case. Error bars are  
272 computed assuming the probability of extinction follows a binomial distribution. For mass vaccination the number  
273 of first-dose vaccinations during the period is the same as in the combined cl. size=1 of the same scenario. **B**  
274 Average attack rate two months after first detected case for the enhanced TTI scenario. **C** Average attack rate  
275 two months after first detected case for the baseline TTI scenario. In panel B and C error bars are the standard  
276 error from 8000 stochastic realisations. In all panels we assume the following parameters:  $R=1.2$ ; Initial immunity  
277 26%; 81% and 33% for 60+ and <60 already vaccinated at the beginning, respectively; no reduction in contacts  
278 due to social distancing or teleworking. Corresponding incidence curves are reported in Figure S7 of  
279 Supplementary Information.

## 280 **Discussion**

281 As of July 2021, social distancing and NPI intervention started to be lifted in many Western  
282 countries owing to the decrease in COVID-19 incidence and increase in vaccination  
283 coverage. However, cases have recently started to rise again, due to the more transmissible  
284 Delta variant. Under these circumstances the prospects for getting back to normal are  
285 becoming short-lived<sup>1,26-30</sup>. More transmissible viruses call for vaccination of a larger  
286 proportion of the population. Vaccination must be made more accessible and able to adapt to  
287 a rapidly evolving epidemic situation<sup>6</sup>. In this context, we have here analysed the reactive  
288 vaccination of workplaces, universities and schools to assess its potential role in managing  
289 the epidemic.

290 We presented an agent-based model that accounts for the key factors affecting the  
291 effectiveness of reactive vaccination: disease natural history, vaccine characteristic, individual  
292 contact behaviour, social distancing interventions in place and logistic constraints. Model  
293 results suggest that: First, reactive vaccination would have a stronger impact on the COVID-  
294 19 epidemic than non-reactive vaccination strategies, when the comparison is done at equal  
295 number of doses within the two months. Second, combining reactive and mass vaccination  
296 would be more effective than mass vaccination alone in both mitigating the sustained spread  
297 and containing a flare-up in a context of diffusion of an emerging variant of concern (VOC).  
298 Third, for the reactive strategy to be effective, vaccines should be administered quickly - i.e.  
299 right after the detection of the first case. In addition, when the goal is to contain a flare-up,  
300 reactive vaccination should be combined with enhanced TTI.

301 Reactive vaccination has been studied for smallpox, cholera and measles, among others<sup>7-</sup>  
302<sup>9,31,32</sup>. Hotspot vaccination was found to help in cholera outbreak response by both modelling  
303 studies and outbreak investigation<sup>32,33</sup>. It may target geographic areas defined at spatial  
304 resolution as diverse as districts within a country, or neighbourhoods within a city, according  
305 to the situation. For Ebola and smallpox ring vaccination was successfully adopted to  
306 accelerate epidemic containment<sup>7-9</sup>. For these infections, vaccine-induced immunity mounts

307 rapidly compared to the incubation period and contacts of an index case can be found before  
308 they start transmitting since pre-symptomatic and asymptomatic transmission is almost  
309 absent. Ring vaccination is also likely effective when the vaccine has post-exposure effects<sup>10</sup>  
310 - e.g. hepatitis A, B, measles, rabies and smallpox. Reactive vaccination of schools and  
311 university campuses has been implemented in the past to contain outbreaks of meningitis<sup>34</sup>  
312 and measles<sup>35,36</sup>.

313 For COVID-19, the use of reactive vaccination has been reported in Ontario, the UK,  
314 Germany, France, among others<sup>6,37-42</sup>. In these places, vaccines were directed to  
315 communities, neighbourhoods or building complexes with a large number of infections or  
316 presenting epidemic clusters or surge of cases due to virus variants. The goal of these  
317 campaigns was to minimise the spread of the virus, but it also addressed inequalities in  
318 access and increased fairness, since a surge of cases may happen where people have  
319 difficulty in isolating due to poverty and house crowding<sup>43</sup>. In France, reactive vaccination  
320 was implemented to contain the emergence of variants of concerns in the municipalities of  
321 Bordeaux, Strasbourg and Brest<sup>40-42</sup>. In the municipality of Strasbourg, vaccination slots  
322 dedicated to students were created following the identification of a Delta cluster in an art  
323 school<sup>40</sup>. Despite the interest in the strategy and its inclusion in the COVID-19 response  
324 plans, very limited work has been done so far to quantify its effectiveness<sup>44,45</sup>. A modelling  
325 study on ring-vaccination suggested that the strategy could be valuable if the vaccine has  
326 post-exposure efficacy and a large proportion of contacts could be identified<sup>45</sup>. Still, post-  
327 exposure effects of the vaccine remain currently under-investigated,<sup>46</sup> and it is likely that the  
328 vaccination of the first ring of contacts alone would bring little benefit. We have here tested  
329 reactive vaccination of workplaces and schools, since focusing on these settings may be an  
330 efficient way to easily reach an extended group of contacts. Workplaces have been found to  
331 be an important setting for COVID-19 transmission, especially specific workplaces where  
332 conditions are more favourable for spreading<sup>47,48</sup>. University settings also cover a central role  
333 in the COVID-19 transmission, due to the higher number of contacts among students,  
334 particularly if sharing common spaces in residence accommodations<sup>49</sup>. Model results show  
335 that reactive vaccination of these settings could have a stronger impact than simply  
336 reinforcing vaccination as in hotspot strategies.

337 However, the feasibility and advantage of the inclusion of reactive vaccination imply a trade-  
338 off between epidemic intensity and logistic constraints. At a high incidence level, combining  
339 reactive and mass vaccination would substantially decrease the attack rate compared to  
340 mass vaccination for the same number of doses, but the large initial demand in vaccines may  
341 exceed the available stockpiles. Even with large enough stockpiles, issues like the timely

342 deployment of additional personnel in mobile vaccine units and the need to quickly inform the  
343 population by communication campaigns must be solved to guarantee the success of the  
344 campaign. We explored with the model the key variables that would impact the strategy  
345 effectiveness. Delaying the deployment of vaccines in workplaces/schools upon the detection  
346 of a case (from 2 to 4 days on average) would not have a strong impact on its effectiveness -  
347 relative reduction going from 29% to 27% in Figure 3D. However, vaccines should be  
348 deployed at the detection of the first case to avoid substantially limiting the impact of the  
349 strategy - e.g. the relative reduction goes from 29% to 15% when workplaces/schools are  
350 vaccinated at the detection of 5 cases (Figure 3E). At a low incidence level, the reactive  
351 strategy would require a few extra doses in a few workplaces/schools, but the advantage with  
352 respect to mass vaccination is overall reduced in this case.

353 Parameters that could greatly impact the effectiveness of reactive vaccination in containing a  
354 flare-up of a new variant have been explored. We found that an early start of the reactive  
355 vaccination campaign since the detection of the first VOC case was required. This requires  
356 that tests for the detection of variants must be carried out quickly and with large coverage. In  
357 France genomic surveillance has ramped up since the emergence of the Alpha variant in late  
358 2020, with nationwide surveys every two weeks involving the full genome sequencing of  
359 randomly selected positive samples<sup>50</sup>. Approximately 50% of positive tests are also screened  
360 for key mutations to monitor the circulation of variants registered as VOC or VUI<sup>50</sup>. While  
361 these volumes of screening may be regarded as sufficient to quickly identify the presence of  
362 variants, the quick rising of large clusters of cases is possible, notably due to super spreading  
363 events, becoming increasingly frequent as social restrictions relax. Second, reactive  
364 vaccination must be part of a wider response plan, including notably a strong intensification of  
365 TTI<sup>51</sup>. Rapid and efficient TTI increases the chance of epidemic containment on its own, but it  
366 is also instrumental to the success of reactive vaccination as it allows triggering vaccination in  
367 households, workplaces and schools. Third, an increased level of vaccine uptake is essential  
368 for reactive vaccination to be of interest. Only 66% of the [18,65] years-old population  
369 declared to be willing to get the vaccine in the last periodic survey by Public Health France<sup>23</sup>.  
370 Upward trends in vaccine uptake have been observed as the vaccination campaign unfolds,  
371 thanks to the incentives by public health authorities, the communication effort and the strong  
372 evidence regarding vaccine efficacy. Yet, at the time of writing only ~66% of 18+ years old  
373 had received at least one dose<sup>22</sup>. As the proportion of people who declare to refuse the  
374 COVID-19 vaccine is between 10% and 15% in France,<sup>52</sup> one could hope that a large  
375 proportion of people who did not get the vaccine already would accept it if it was more  
376 accessible, had a benefit to vaccination or received an incentive to vaccinate. An increase in  
377 vaccine uptake was indeed observed in the context of a reactive vaccination campaign during

378 the course of a measles outbreak<sup>5</sup>. Therefore reactive vaccination could be an important way  
379 to improve access to vaccination - especially for the hard-to-reach population - and potentially  
380 increase acceptability, e.g. due to risk perception.

381 The study is affected by several limitations. First, the synthetic population used in the study  
382 accounts for the repartition of contacts across workplaces, schools, households, etc.,  
383 informed by contact surveys. However, numbers of contacts and risk of transmission could  
384 vary greatly according to the kind of occupation. The synthetic population accounts for this  
385 variability assuming that the average number of contacts from one workplace to another is  
386 gamma distributed<sup>12</sup>. Still, no data were available to inform the model in this respect. Second,  
387 we model vaccination uptake according to age only, when it is determined by several  
388 sociodemographic factors. Clusters of vaccine hesitant individuals may play an important role  
389 in the dynamics and facilitate the epidemic persistence in the population, as it is described for  
390 measles<sup>53</sup>. As vaccination coverage increases, heterogeneities in attitude toward vaccination  
391 will likely have an increasing impact. Third, the baseline analysis is based on vaccine efficacy  
392 parameters for the wild type virus that is best documented. Vaccine protection may be  
393 reduced or require more time to establish with VOC infection. For example, vaccine protection  
394 was lower for the Delta variant than for the historical variant, especially in those who had  
395 received only one dose<sup>54-56</sup>. Scenarios with slower rise of vaccine protection - parametrised  
396 from<sup>25</sup> - and 30% reduced efficacy against infection were tested in the sensitivity analysis.  
397 Simulation shows a more limited impact of vaccination in this case, regardless of the strategy,  
398 but the benefit of reactive vaccination with respect to non-reactive vaccination remains,  
399 although reduced. Updated analyses should be done once more precise vaccine efficacy  
400 parameters are available.

## 401 **Methods**

### 402 **Synthetic population**

403 We use a synthetic population for a French municipality based on the National Institute of  
404 Statistics and Economic Studies (INSEE) censuses and French contact survey information  
405<sup>12,57</sup>. This includes the following input files: i) a setting-specific, time-varying network of daily  
406 face-to-face contacts; ii) the maps between individuals and their age, iii) between individuals  
407 and the household they belong to, iv) between individuals and their school, v) and between  
408 individuals and their workplace. The synthetic population has age pyramid, household  
409 composition, number of workplaces by size, and number of schools by type, reproducing  
410 INSEE statistics. Daily face-to-face contacts among individuals are labelled according to the  
411 setting in which they occur (either household, workplace, school, community or transport) and

412 they have assigned a daily frequency of activation, to explicitly model recurrent and sporadic  
413 contacts. We consider the municipality of Metz in the Grand Est region, which has 117,492  
414 inhabitants, 131 schools (from kindergarten to University) and 2888 workplaces (Figure 1A).  
415 Detailed description of how the population was generated is provided in <sup>12</sup>. Information about  
416 how to access population files is provided in the Data availability section.

## 417 **Overview of the model**

418 The model is written in C/C++, and is stochastic and discrete-time. It accounts for the  
419 following components: (i) teleworking and social distancing, (ii) COVID-19 transmission,  
420 accounting for the effect of the vaccine; (iii) test-trace-isolate; (iv) vaccine deployment. Model  
421 output includes time series of incidence (clinical and subclinical cases), detailed information  
422 on infected cases (time of infection, age, vaccination status), vaccines administered  
423 according to the strategy, number of workplaces where vaccines are deployed. Different  
424 epidemic scenarios are explored and compared. In the Supplementary Information we also  
425 analyse hospitalisation entries, deaths, ICU entries, life-year lost, quality-adjusted life-year,  
426 hospital bed and ICU bed occupancy. These quantities are computed by postprocessing  
427 output files containing the detailed information on infected cases.

## 428 **Teleworking and social distancing**

429 To model social distancing, we assume a proportion of nodes are absent from work, modelled  
430 by erasing working contacts and transport contacts of these nodes. We also remove a  
431 proportion of contacts from the community layer to account for reduction in social encounters  
432 due to closure of restaurants and other leisure activities. We choose plausible reduction  
433 values in the range reported by google mobility reports <sup>58</sup> during the first half of 2021 in  
434 France. Specifically, we set the reduction of contacts in the community to 30% within the  
435 range of the mobility reduction in places of retail and recreation (between ~50% to ~5%)  
436 measured from January to June 2021, and the fraction of teleworkers to 20% within the  
437 ballpark of reduction values registered for workplaces in the same period - in general between  
438 ~35% to ~10%. Telework and social distancing is implemented at the beginning of the  
439 simulation and remains constant for the duration of the simulation. Scenarios with no  
440 reduction in contacts are also considered.

## 441 **COVID-19 transmission model**

442 Transmission model is an extension of the model in <sup>12</sup> (see Figure 1D). This accounts for  
443 heterogeneous susceptibility and severity across age groups <sup>59,60</sup>, the presence of an  
444 exposed and a pre-symptomatic stage <sup>11</sup>, and two different levels of infection outcome -

445 subclinical, corresponding to asymptomatic infection and pauci-symptomatic, and clinical,  
446 corresponding to moderate to critical infection<sup>59,61</sup>. Precisely, susceptible individuals, if in  
447 contact with infectious ones, may get infected and enter the exposed compartment ( $E$ ). After  
448 an average latency period  $\epsilon^{-1}$  they become infectious, developing a subclinical infection ( $I_{sc}$ )  
449 with age-dependent probability  $p_{sc}^A$  and a clinical infection ( $I_c$ ) otherwise. From  $E$ , before  
450 entering either  $I_{sc}$  or  $I_c$ , individuals enter first a prodromal phase (either  $I_{p,sc}$  or  $I_{p,c}$ ), that lasts  
451 on average  $\mu_p^{-1}$  days. Compared to  $I_{p,c}$  and  $I_c$  individuals, individuals in the  $I_{p,sc}$  and  $I_{sc}$   
452 compartments have reduced transmissibility rescaled by a factor  $\beta_l$ . With rate  $\mu$  infected  
453 individuals become recovered. Age-dependent susceptibility and age-dependant probability  
454 of clinical symptoms are parametrised from<sup>59</sup>. In addition, transmission depends on setting as  
455 in<sup>12</sup>. Parameters are summarised in Table S1 of the Supplementary Information.

456 We model vaccination with a leaky vaccine, partially reducing both the risk of infection (i.e.  
457 reduction in susceptibility,  $VE_S$ ) and infection-confirmed symptomatic illness ( $VE_{SP}$ )<sup>17</sup>. Level of  
458 protection increases progressively after the inoculation of the first dose. In our model we did  
459 not explicitly account for the two-dose administration, but we accounted for two levels of  
460 protection – e.g. a first one approximately in between of the two doses and a second one  
461 after the second dose. Vaccine efficacy was zero immediately after inoculation, mounting  
462 then to an intermediate level ( $VE_{S,1}$  and  $VE_{SP,1}$ ) and a maximum level later ( $VE_{S,2}$  and  $VE_{SP,2}$ ).  
463 This is represented through the compartmental model in Figure 1C. Upon administering the  
464 first dose,  $S$  individuals become,  $S^{V,0}$ , i.e. individuals that are vaccinated, but have no vaccine  
465 protection. If they do not become infected, they enter the stage  $S^{V,1}$  at rate  $\nu_1$ , where they are  
466 partially protected, then stage  $S^{V,2}$  at rate  $\nu_2$  where vaccine protection is maximum.  $S^{V,1}$  and  
467  $S^{V,2}$  individuals have reduced probability of getting infected by a factor  $r_{S,1} = (1 - VE_{S,1})$  and  
468  $r_{S,2} = (1 - VE_{S,2})$ , respectively. In case of infection,  $S^{V,2}$  individuals progress first to exposed  
469 vaccinated ( $E^V$ ), then to either preclinical or pre-subclinical vaccinated ( $I_{p,c}^V$  or  $I_{p,sc}^V$ ) that are  
470 followed by clinical and subclinical vaccinated respectively ( $I_c^V$  or  $I_{sc}^V$ ). Probability of becoming  
471  $I_{p,c}^V$  from  $E^V$  is reduced of a factor  $r_{c,2} = (1 - VE_{SP,2})(1 - VE_{S,2})^{-1}$ . For the  $S^{V,1}$  individuals  
472 that get infected we assume a polarised vaccine effect, i.e. they can enter either in  $E^V$ , with  
473 probability  $p_V$ , or in  $E$  (Figure 1D). The value of  $p_V$  can be set based on  $VE_{SP,1}$  through the  
474 relation  $(1 - VE_{SP,1}) = (1 - VE_{S,1})(p_V r_{c,2} + (1 - p_V))$ .

475 Under the assumption that no serological/virological/antigenic test is done before vaccine  
476 administration, the vaccine is administered to all individuals, except for clinical cases who  
477 show clear signs of the disease or individuals that were detected as infected by the TTI in  
478 place. In our model a vaccine administered to infected or recovered individuals has no effect.

479 In the baseline scenario we parametrise  $VE_{SP,1}$  and  $VE_{SP,2}$  based on the vaccine efficacies  
480 estimated in clinical trials<sup>18,19</sup>. We then set  $VE_{S,1}$  and  $VE_{S,2}$  by keeping the same ratio  
481 estimated in<sup>25</sup>. In the sensitivity analysis we assume a more conservative hypothesis, by  
482 calibrating the model entirely from<sup>25</sup>. We also explore a reduction of 30% in  $VE_{S,1}$  and  $VE_{S,2}$ .  
483 Parameters are listed in Table S2 of the Supplementary Information.

#### 484 **Test-trace-isolate**

485 We model a baseline TTI as regularly, in place in France, accounting for case detection,  
486 household isolation and manual contact tracing. Fifty percent of individuals with clinical  
487 symptoms were assumed to get tested and to isolate if positive. We assume an exponentially  
488 distributed delay from symptoms onset to case detection and its isolation with 3.6 days on  
489 average. Once a case is detected, his/her household members isolate with probability  $p_{ct,HH}$ ,  
490 while other contacts isolate with probabilities  $p_{ct,A}$  and  $p_{ct,oth}$ , for acquaintances and sporadic  
491 contacts, respectively. In addition to the detection of clinical cases, we assumed that a  
492 proportion of subclinical cases were also identified (10%). Isolated individuals resume normal  
493 daily life after 10 days unless they still have clinical symptoms after the time has passed.  
494 They may, however, decide to drop out from isolation each day with a probability of 13% if  
495 they do not have symptoms<sup>62</sup>.

496 In the scenario of virus re-introduction, we consider enhanced TTI, corresponding to a  
497 situation of case investigation, screening campaign and sensibilisation (prompting higher  
498 compliance to isolation). We assume a higher detection of clinical and subclinical cases  
499 (100% and 50% respectively), perfect compliance to isolation by the index case and  
500 household members and a three-fold increase in contacts identified outside the household.

501 Step-by-step description of contact tracing is provided in the Supplementary Information.  
502 Parameters for baseline TTI are provided in Table S3, while parameters for enhanced TTI are  
503 provided in Table S4.

#### 504 **Vaccination strategies**

505 A vaccine opinion (willingness or not to vaccinate) is stochastically assigned to each  
506 individual at the beginning of the simulation depending on age (below/above 65). Opinion  
507 does not change during the simulation. In some scenarios we assume that all individuals are  
508 willing to accept the vaccine in case of reactive vaccination, while maintaining the opinion  
509 originally assigned to them when the vaccine is proposed in the context of non-reactive  
510 vaccination. Only individuals above a threshold age,  $a_{th,v} = 18$  years old, are vaccinated. We

511 assume that a certain fraction of individuals is vaccinated at the beginning of the simulation  
512 according to the age group ([18,60], 60+). We compare the following vaccination strategies:

513 *Mass:*  $V_{daily}$  randomly selected individuals are vaccinated each day until a  $V_{tot}$  limit is  
514 reached.

515 *Workplaces/universities:* Random workplaces/universities are selected each day. All  
516 individuals belonging to the place, willing to be vaccinated, and not isolated at home that day  
517 are vaccinated. Individuals in workplaces/universities are vaccinated each day until the daily  
518 limit,  $V_{daily}$  is reached. No more than  $V_{tot}$  individuals are vaccinated during the course of the  
519 simulation. We assume that only workplaces with  $size_{th} = 20$  employees or larger implement  
520 vaccination.

521 *School location:* Random schools, other than universities, are selected each day and a  
522 vaccination campaign is conducted in the places open to all adult household members of  
523 school students. All household members willing to be vaccinated, above the threshold age  
524 and not isolated at home that day are vaccinated. No more than  $V_{daily}$  individuals are  
525 vaccinated each day and no more than  $V_{tot}$  individuals are vaccinated during the course of  
526 the simulation.

527 *Reactive:* When a case is detected, vaccination is done in her/his household with rate  $r_V$ .  
528 When a cluster – i.e. at least  $n_{cl}$  cases detected within a time window of length  $T_{cl}$  – is  
529 detected in a workplace/school, vaccination is done in that place with rate  $r_V$ . In the baseline  
530 scenario, we assume vaccination in workplace/school to be triggered by one single infected  
531 individual ( $n_{cl} = 1$ ). In both household and workplace/school, all individuals belonging to the  
532 place above the threshold age and willing to be vaccinated are vaccinated. Individuals that  
533 were already detected and isolated at home are not vaccinated. No more than  $V_{daily}$   
534 individuals are vaccinated each day and no more than  $V_{tot}$  individuals are vaccinated during  
535 the course of the simulation. In the baseline scenario these quantities are unlimited, i.e. all  
536 individuals to be vaccinated in the context of reactive vaccination are vaccinated.

537 Parameters and their values are summarised in Table S5 of the Supplementary Information.

### 538 **Data availability**

539 The synthetic population used in the analysis is available on github <sup>63</sup>.

### 540 **Code availability**

541 We provide all C/C++ code files of the model on github <sup>63</sup>.

## 542 **References**

- 543 1. Kiem, C. T. *et al.* Short and medium-term challenges for COVID-19 vaccination: from  
544 prioritisation to the relaxation of measures. (2021).
- 545 2. Bubar, K. M. *et al.* Model-informed COVID-19 vaccine prioritization strategies by age and  
546 serostatus. *Science* (2021) doi:10.1126/science.abe6959.
- 547 3. Matrajt, L., Eaton, J., Leung, T. & Brown, E. R. Vaccine optimization for COVID-19: Who  
548 to vaccinate first? *Science Advances* **7**, eabf1374 (2020).
- 549 4. Lu, D. *et al.* Data-driven estimate of SARS-CoV-2 herd immunity threshold in populations  
550 with individual contact pattern variations. *medRxiv* 2021.03.19.21253974 (2021)  
551 doi:10.1101/2021.03.19.21253974.
- 552 5. Le Menach, A. *et al.* Increased measles–mumps–rubella (MMR) vaccine uptake in the  
553 context of a targeted immunisation campaign during a measles outbreak in a vaccine-  
554 reluctant community in England. *Vaccine* **32**, 1147–1152 (2014).
- 555 6. Overview of the implementation of COVID-19 vaccination strategies and deployment plans  
556 in the EU/EEA. *European Centre for Disease Prevention and Control*  
557 [https://www.ecdc.europa.eu/en/publications-data/overview-implementation-covid-19-](https://www.ecdc.europa.eu/en/publications-data/overview-implementation-covid-19-vaccination-strategies-and-deployment-plans)  
558 [vaccination-strategies-and-deployment-plans](https://www.ecdc.europa.eu/en/publications-data/overview-implementation-covid-19-vaccination-strategies-and-deployment-plans) (2021).
- 559 7. Merler, S. *et al.* Containing Ebola at the Source with Ring Vaccination. *PLOS Neglected*  
560 *Tropical Diseases* **10**, e0005093 (2016).
- 561 8. Henao-Restrepo, A. M. *et al.* Efficacy and effectiveness of an rVSV-vectored vaccine  
562 expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination  
563 cluster-randomised trial. *Lancet* (2015) doi:10.1016/S0140-6736(15)61117-5.
- 564 9. Geddes, A. M. The history of smallpox. *Clinics in Dermatology* **24**, 152–157 (2006).
- 565 10. Gallagher, T. & Lipsitch, M. Postexposure Effects of Vaccines on Infectious Diseases.  
566 *Epidemiologic Reviews* **41**, 13–27 (2019).
- 567 11. He, X. *et al.* Temporal dynamics in viral shedding and transmissibility of COVID-19.  
568 *Nature Medicine* 1–4 (2020) doi:10.1038/s41591-020-0869-5.
- 569 12. López, J. A. M. *et al.* Anatomy of digital contact tracing: Role of age, transmission

- 570 setting, adoption and case detection. *Science Advances* eabd8750 (2021)
- 571 doi:10.1126/sciadv.abd8750.
- 572 13. Ajelli, M. *et al.* Comparing large-scale computational approaches to epidemic  
573 modeling: Agent-based versus structured metapopulation models. *BMC Infectious*  
574 *Diseases* **10**, 190 (2010).
- 575 14. Chao, D. L., Halloran, M. E., Obenchain, V. J. & Jr, I. M. L. FluTE, a Publicly  
576 Available Stochastic Influenza Epidemic Simulation Model. *PLOS Comput Biol* **6**,  
577 e1000656 (2010).
- 578 15. Willem, L., Verelst, F., Bilcke, J., Hens, N. & Beutels, P. Lessons from a decade of  
579 individual-based models for infectious disease transmission: a systematic review (2006-  
580 2015). *BMC Infectious Diseases* **17**, 612 (2017).
- 581 16. Liu, Q.-H. *et al.* Measurability of the epidemic reproduction number in data-driven  
582 contact networks. *PNAS* **115**, 12680–12685 (2018).
- 583 17. Basta, N. E., Halloran, M. E., Matrajt, L. & Longini, I. M. Estimating influenza vaccine  
584 efficacy from challenge and community-based study data. *Am J Epidemiol* **168**, 1343–  
585 1352 (2008).
- 586 18. Polack, F. P. *et al.* Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.  
587 *New England Journal of Medicine* **383**, 2603–2615 (2020).
- 588 19. Baden, L. R. *et al.* Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.  
589 *New England Journal of Medicine* **384**, 403–416 (2021).
- 590 20. Proportion de la population infectée par SARS-CoV-2. [https://modelisation-](https://modelisation-covid19.pasteur.fr/realtime-analysis/infected-population/)  
591 [covid19.pasteur.fr/realtime-analysis/infected-population/](https://modelisation-covid19.pasteur.fr/realtime-analysis/infected-population/).
- 592 21. Hozé, N. *et al.* Monitoring the proportion of the population infected by SARS-CoV-2  
593 using age-stratified hospitalisation and serological data: a modelling study. *The Lancet*  
594 *Public Health* **6**, e408–e415 (2021).
- 595 22. Tableau de bord COVID-19. [https://www.gouvernement.fr/info-coronavirus/carte-et-](https://www.gouvernement.fr/info-coronavirus/carte-et-donnees#vue_d_ensemble-taux_d_incidence)  
596 [donnees#vue\\_d\\_ensemble-taux\\_d\\_incidence](https://www.gouvernement.fr/info-coronavirus/carte-et-donnees#vue_d_ensemble-taux_d_incidence).
- 597 23. SPF. COVID-19 : point épidémiologique du 6 mai 2021.

- 598 [https://www.santepubliquefrance.fr/maladies-et-traumatismes/maladies-et-infections-](https://www.santepubliquefrance.fr/maladies-et-traumatismes/maladies-et-infections-respiratoires/infection-a-coronavirus/documents/bulletin-national/covid-19-point-epidemiologique-du-6-mai-2021)  
599 [respiratoires/infection-a-coronavirus/documents/bulletin-national/covid-19-point-](https://www.santepubliquefrance.fr/maladies-et-traumatismes/maladies-et-infections-respiratoires/infection-a-coronavirus/documents/bulletin-national/covid-19-point-epidemiologique-du-6-mai-2021)  
600 [epidemiologique-du-6-mai-2021](https://www.santepubliquefrance.fr/maladies-et-traumatismes/maladies-et-infections-respiratoires/infection-a-coronavirus/documents/bulletin-national/covid-19-point-epidemiologique-du-6-mai-2021).
- 601 24. CoviPrev : une enquête pour suivre l'évolution des comportements et de la santé  
602 mentale pendant l'épidémie de COVID-19. [https://www.santepubliquefrance.fr/etudes-et-](https://www.santepubliquefrance.fr/etudes-et-enquetes/coviprev-une-enquete-pour-suivre-l-evolution-des-comportements-et-de-la-sante-mentale-pendant-l-epidemie-de-covid-19)  
603 [enquetes/coviprev-une-enquête-pour-suivre-l'évolution-des-comportements-et-de-la-](https://www.santepubliquefrance.fr/etudes-et-enquetes/coviprev-une-enquete-pour-suivre-l-evolution-des-comportements-et-de-la-sante-mentale-pendant-l-epidemie-de-covid-19)  
604 [sante-mentale-pendant-l-epidemie-de-covid-19](https://www.santepubliquefrance.fr/etudes-et-enquetes/coviprev-une-enquete-pour-suivre-l-evolution-des-comportements-et-de-la-sante-mentale-pendant-l-epidemie-de-covid-19).
- 605 25. Dagan, N. *et al.* BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass  
606 Vaccination Setting. *New England Journal of Medicine* (2021)  
607 doi:10.1056/NEJMoa2101765.
- 608 26. Huang, B. *et al.* Integrated vaccination and physical distancing interventions to  
609 prevent future COVID-19 waves in Chinese cities. *Nat Hum Behav* **5**, 695–705 (2021).
- 610 27. Moore, S., Hill, E. M., Tildesley, M. J., Dyson, L. & Keeling, M. J. Vaccination and  
611 non-pharmaceutical interventions for COVID-19: a mathematical modelling study. *The*  
612 *Lancet Infectious Diseases* **21**, 793–802 (2021).
- 613 28. Yang, J. *et al.* Despite vaccination, China needs non-pharmaceutical interventions to  
614 prevent widespread outbreaks of COVID-19 in 2021. *Nat Hum Behav* 1–12 (2021)  
615 doi:10.1038/s41562-021-01155-z.
- 616 29. Gozzi, N., Bajardi, P. & Perra, N. The importance of non-pharmaceutical interventions  
617 during the COVID-19 vaccine rollout. *medRxiv* 2021.01.09.21249480 (2021)  
618 doi:10.1101/2021.01.09.21249480.
- 619 30. Bosetti, P. *et al.* Epidemiology and control of SARS-CoV-2 epidemics in partially  
620 vaccinated populations: a modeling study applied to France. (2021).
- 621 31. Grais, R. F. *et al.* Time is of the essence: exploring a measles outbreak response  
622 vaccination in Niamey, Niger. *Journal of The Royal Society Interface* (2007)  
623 doi:10.1098/rsif.2007.1038.
- 624 32. Finger, F. *et al.* The potential impact of case-area targeted interventions in response  
625 to cholera outbreaks: A modeling study. *PLOS Medicine* **15**, e1002509 (2018).

- 626 33. Martin, S. *et al.* Post-licensure deployment of oral cholera vaccines: a systematic  
627 review. *Bull World Health Organ* **92**, 881–893 (2014).
- 628 34. Capitano, B., Dillon, K., LeDuc, A., Atkinson, B. & Burman, C. Experience  
629 implementing a university-based mass immunization program in response to a  
630 meningococcal B outbreak. *Human Vaccines & Immunotherapeutics* **15**, 717–724 (2019).
- 631 35. Pegorie, M. *et al.* Measles outbreak in Greater Manchester, England, October 2012 to  
632 September 2013: epidemiology and control. *Eurosurveillance* **19**, 20982 (2014).
- 633 36. Kirolos, A. *et al.* Imported case of measles in a university setting leading to an  
634 outbreak of measles in Edinburgh, Scotland from September to December 2016.  
635 *Epidemiology & Infection* **146**, 741–746 (2018).
- 636 37. Ontario's COVID-19 vaccination plan. *COVID-19 (coronavirus) in Ontario*  
637 <https://covid-19.ontario.ca/ontarios-covid-19-vaccination-plan>.
- 638 38. Covid-19: More variant hotspots to get surge tests and jabs. *BBC News* (2021).
- 639 39. Welle (www.dw.com), D. COVID: Cologne project aims to vaccinate urban hot spots |  
640 DW | 08.05.2021. *DW.COM* [https://www.dw.com/en/covid-cologne-project-aims-to-](https://www.dw.com/en/covid-cologne-project-aims-to-vaccinate-urban-hot-spots/a-57472989)  
641 [vaccinate-urban-hot-spots/a-57472989](https://www.dw.com/en/covid-cologne-project-aims-to-vaccinate-urban-hot-spots/a-57472989).
- 642 40. COVID-19 : présence du variant indien dans l'Eurométropole et plan d'actions  
643 immédiat. [http://www.grand-est.ars.sante.fr/covid-19-presence-du-variant-indien-dans-](http://www.grand-est.ars.sante.fr/covid-19-presence-du-variant-indien-dans-leurometropole-et-plan-dactions-immediat)  
644 [leurometropole-et-plan-dactions-immediat](http://www.grand-est.ars.sante.fr/covid-19-presence-du-variant-indien-dans-leurometropole-et-plan-dactions-immediat).
- 645 41. COVID-19 : en Pays de Brest, la vaccination s'accélère.  
646 <http://www.bretagne.ars.sante.fr/covid-19-en-pays-de-brest-la-vaccination-saccelere>.
- 647 42. Communiqué de presse - Covid-19 - La nécessité de se faire vacciner rapidement  
648 pour éviter la propagation du virus, notamment du variant delta. [http://www.nouvelle-](http://www.nouvelle-aquitaine.ars.sante.fr/communique-de-presse-covid-19-la-necessite-de-se-faire-vacciner-rapidement-pour-eviter-la)  
649 [aquitaine.ars.sante.fr/communique-de-presse-covid-19-la-necessite-de-se-faire-vacciner-](http://www.nouvelle-aquitaine.ars.sante.fr/communique-de-presse-covid-19-la-necessite-de-se-faire-vacciner-rapidement-pour-eviter-la)  
650 [rapidement-pour-eviter-la](http://www.nouvelle-aquitaine.ars.sante.fr/communique-de-presse-covid-19-la-necessite-de-se-faire-vacciner-rapidement-pour-eviter-la).
- 651 43. Valdano, E., Lee, J., Bansal, S., Rubrichi, S. & Colizza, V. Highlighting socio-  
652 economic constraints on mobility reductions during COVID-19 restrictions in France can  
653 inform effective and equitable pandemic response. *Journal of Travel Medicine* **28**, (2021).

- 654 44. Xu, W., Su, S. & Jiang, S. Ring vaccination of COVID-19 vaccines in medium- and  
655 high-risk areas of countries with low incidence of SARS-CoV-2 infection. *Clin Transl Med*  
656 **11**, e331 (2021).
- 657 45. MacIntyre, C. R., Costantino, V. & Trent, M. Modelling of COVID-19 vaccination  
658 strategies and herd immunity, in scenarios of limited and full vaccine supply in NSW,  
659 Australia. *Vaccine* (2021) doi:10.1016/j.vaccine.2021.04.042.
- 660 46. Muller, C. P. Can integrated post-exposure vaccination against SARS-COV2 mitigate  
661 severe disease? *The Lancet Regional Health – Europe* **5**, (2021).
- 662 47. Althouse, B. M. *et al.* Superspreading events in the transmission dynamics of SARS-  
663 CoV-2: Opportunities for interventions and control. *PLOS Biology* **18**, e3000897 (2020).
- 664 48. Leclerc, Q. J. *et al.* What settings have been linked to SARS-CoV-2 transmission  
665 clusters? *Wellcome Open Research* **5**, 83 (2020).
- 666 49. Christensen, H. *et al.* COVID-19 transmission in a university setting: a rapid review of  
667 modelling studies. *medRxiv* 2020.09.07.20189688 (2020)  
668 doi:10.1101/2020.09.07.20189688.
- 669 50. Coronavirus : circulation des variants du SARS-CoV-2.  
670 [https://www.santepubliquefrance.fr/dossiers/coronavirus-covid-19/coronavirus-circulation-](https://www.santepubliquefrance.fr/dossiers/coronavirus-covid-19/coronavirus-circulation-des-variants-du-sars-cov-2)  
671 [des-variants-du-sars-cov-2.](https://www.santepubliquefrance.fr/dossiers/coronavirus-covid-19/coronavirus-circulation-des-variants-du-sars-cov-2)
- 672 51. Pullano, G. *et al.* Underdetection of COVID-19 cases in France threatens epidemic  
673 control. *Nature* 1–9 (2020) doi:10.1038/s41586-020-03095-6.
- 674 52. Spire, A., Bajos, N. & Silberzan, L. Social inequalities in hostility toward vaccination  
675 against Covid-19. *medRxiv* 2021.06.07.21258461 (2021)  
676 doi:10.1101/2021.06.07.21258461.
- 677 53. Metcalf, C. J. E. *et al.* Seven challenges in modeling vaccine preventable diseases.  
678 *Epidemics* **10**, 11–15 (2015).
- 679 54. Sheikh, A., McMenamin, J., Taylor, B. & Robertson, C. SARS-CoV-2 Delta VOC in  
680 Scotland: demographics, risk of hospital admission, and vaccine effectiveness. *The*  
681 *Lancet* **397**, 2461–2462 (2021).

- 682 55. Nasreen, S. *et al.* *Effectiveness of COVID-19 vaccines against variants of concern,*  
683 *Canada.* <http://medrxiv.org/lookup/doi/10.1101/2021.06.28.21259420> (2021)  
684 [doi:10.1101/2021.06.28.21259420](https://doi.org/10.1101/2021.06.28.21259420).
- 685 56. Investigation of SARS-CoV-2 variants of concern: technical briefings. *GOV.UK*  
686 [https://www.gov.uk/government/publications/investigation-of-novel-sars-cov-2-variant-](https://www.gov.uk/government/publications/investigation-of-novel-sars-cov-2-variant-variant-of-concern-20201201)  
687 [variant-of-concern-20201201](https://www.gov.uk/government/publications/investigation-of-novel-sars-cov-2-variant-variant-of-concern-20201201).
- 688 57. Béraud, G. *et al.* The French Connection: The First Large Population-Based Contact  
689 Survey in France Relevant for the Spread of Infectious Diseases. *PLOS ONE* **10**,  
690 e0133203 (2015).
- 691 58. COVID-19 Community Mobility Report. *COVID-19 Community Mobility Report*  
692 <https://www.google.com/covid19/mobility?hl=en>.
- 693 59. Davies, N. G. *et al.* Age-dependent effects in the transmission and control of COVID-  
694 19 epidemics. *Nature Medicine* 1–7 (2020) [doi:10.1038/s41591-020-0962-9](https://doi.org/10.1038/s41591-020-0962-9).
- 695 60. Di Domenico, L., Pullano, G., Sabbatini, C. E., Boëlle, P.-Y. & Colizza, V. Modelling  
696 safe protocols for reopening schools during the COVID-19 pandemic in France. *Nat*  
697 *Commun* **12**, 1073 (2021).
- 698 61. Riccardo, F. *et al.* Epidemiological characteristics of COVID-19 cases and estimates  
699 of the reproductive numbers 1 month into the epidemic, Italy, 28 January to 31 March  
700 2020. *Eurosurveillance* **25**, 2000790 (2020).
- 701 62. Smith, L. E. *et al.* Adherence to the test, trace and isolate system: results from a time  
702 series of 21 nationally representative surveys in the UK (the COVID-19 Rapid Survey of  
703 Adherence to Interventions and Responses [CORSAIR] study). *medRxiv* (2020)  
704 [doi:10.1101/2020.09.15.20191957](https://doi.org/10.1101/2020.09.15.20191957).
- 705 63. PYB-SU. PYB-SU/ReactiveVaccination. [https://github.com/PYB-](https://github.com/PYB-SU/ReactiveVaccination)  
706 [SU/ReactiveVaccination](https://github.com/PYB-SU/ReactiveVaccination) (2021).

## 707 **Acknowledgements**

708 We acknowledge financial support from Haute Autorité de Santé; the ANR and Fondation de

709 France through the project NoCOV (00105995); the Municipality of Paris  
710 (<https://www.paris.fr/>) through the programme Emergence(s); EU H2020 grants MOOD  
711 (H2020-874850), and RECOVER (H2020-101003589); Institut des Sciences du Calcul et de  
712 la Donnée (ISCD).  
713

714 **Supplementary Information**

715

716 **Additional Methods**

717 **COVID-19 transmission model**

718 We provide here in the following the parameter values for transmission and infection natural  
 719 history (Table S1), and the effect of vaccination (Table S2). For a detailed explanation of the  
 720 transmission model without vaccination we refer to <sup>1</sup>.

721 **Table S1. Transmission parameters and their baseline values.**

Parameter	Description	Value	Source
$IP$	Incubation period	5.2 days	2
$\mu_p$	Rate of developing symptoms for pre-symptomatic individuals	$(2.3 \text{ days})^{-1}$	3
$\epsilon$	Rate of becoming infectious for exposed individuals	$(2.9 \text{ days})^{-1}$	$IP - \mu_p^{-1}$
$\mu$	Recovery rate	$(7 \text{ days})^{-1}$	3
$\beta_I$	transmissibility rescaling according to the infectious stage	0.51 for $I_{p,sc}, I_{sc}$ 1 for $I_{p,c}, I_c$	4
$\omega_s$	Transmission risk by setting (network layer)	1 for $H$ layer 0.3 for $C$ layer 0.5 otherwise	1

722

723 **Table S2. Vaccine efficacy parameters and their baseline values.**

Parameter	Description	Baseline value	Source
$r_{S,1}$	reduction in susceptibility in the partial-protection stage	0.48	from $VE_S = 52\%$ estimated at 7 days from the first dose in <sup>5,6</sup>
$\nu_1$	Rate of developing partial protection after vaccine uptake	$(1 \text{ week})^{-1}$	5,6

$r_{S,2}$	reduction in susceptibility in the maximum-protection stage	0.13	from $VE_S = 87\%$ estimated at 14 days from the first dose in <sup>5,6</sup>
$r_{c,2}$	reduction in the probability of developing clinical symptoms in the maximum-protection stage	0.76	from $VE_{SP} = 90\%$ estimated at one week after the second dose, i.e. 28 days after first dose <sup>5,6</sup>
$\nu_2$	Rate of developing maximum protection after entering the partial-protection stage	$(1 \text{ week})^{-1}$	One week after the second dose, i.e. 14 days after first dose <sup>5,6</sup>
$p_V$	Probability of transition between $S^{V,1}$ and $E^V$	0.86	Computed from the parameters above and $VE_{SP} = 62\%$ estimated at 7 days from the first dose in <sup>5,6</sup>

724

## 725 Test-trace-isolate

726 We model case detection and isolation, combined with tracing and isolation of contacts  
727 according to the following rules:

- 728 • As an individual shows clinical symptoms, s/he is detected with probability  $p_{d,c}$ . If  
729 detected, case confirmation and isolation occur with rate  $r_d$  upon symptoms onset.
- 730 • Subclinical individuals are also detected with probability  $p_{d,sc}$ , and rate  $r_d$ .
- 731 • The index case's household contacts are isolated, with probability  $p_{ct,HH}$ , the same time  
732 the index case is detected and isolated. We assume that these contacts are tested at the  
733 time of isolation and among those all subclinical, clinical, pre-subclinical, and pre-clinical  
734 cases are detected (testing sensitivity 100%).
- 735 • Once the index case is detected, contacts of the index case occurring outside the  
736 household are traced and isolated with an average delay  $r_{ct}^{-1}$ . We define an acquaintance  
737 as a contact occurring frequently, i.e. with a frequency of activation higher than  $f_a$ . We  
738 assume that an acquaintance is detected and isolated with a probability  $p_{ct,A}$ , while other  
739 contacts (i.e. sporadic contacts) are detected and isolated with probability  $p_{ct,sp}$ , with  
740  $p_{ct,A} > p_{ct,sp}$ . We assume that traced contacts are tested at the time of isolation and  
741 among those all subclinical, clinical, pre-subclinical, and pre-clinical cases are detected  
742 (testing sensitivity 100%).

743 • Only contacts (among contacts occurring both in household and outside) occurring within  
744 a window of  $D$  days before index case detection are considered for contact tracing.

745 • The index-case and the contacts are isolated for a duration  $d_I$  (for all infected  
746 compartments) and  $d_{NI}$  (for susceptible and recovered compartments). Contacts with no  
747 clinical symptoms have a daily probability  $p_{drop}$  to drop out from isolation.

748 • For both the case and the contacts, isolation is implemented by assuming no contacts  
749 outside the household and transmission risk per contact within a household reduced by a  
750 factor  $\iota$ .

751 Parameter values are reported in Table S3 and Table S4 for baseline and enhanced TTI,  
752 respectively.

753 **Table S3. Model for test-trace-isolation. Parameters and their values for the baseline case.**

Parameter	Description	Value	Source
$p_{d,c}$	Probability that a clinical case is detected	0.5	
$p_{d,sc}$	Probability that a subclinical case is detected	0.1	
$r_d$	For detected cases, rate of detection, confirmation and beginning of isolation	$0.28 = (3.6 \text{ days})^{-1}$	Average time from onset to testing is 2.6 days <sup>7</sup> . We assume one day to have the test results.
$D$	Length of the period preceding index-case confirmation, used to define a contact	6 days (*)	$\simeq 2 \text{ days} + r_d^{-1}$ (a person is considered to be contact if s/he entered in contact with the index case during a window of 2 days preceding symptoms onset)
$p_{ct,HH}$	Probability that household contacts of an index case are identified and decide to isolate	0.7	
$p_{ct,A}$	Probability that acquaintances of an index case are identified and decide to isolate	0.08	Calibrated to get $\simeq 2.8$ contacts per index case on average (assumed $p_{ct,oth} = p_{ct,A}/10$ ) <sup>7</sup>

$p_{ct,Oth}$	Probability that the contacts of a detected case outside household are compliant to isolation	0.008	Calibrated to get $\approx 2.8$ contacts per index case on average (assumed $p_{ct,Oth} = p_{ct,A}/10$ ) <sup>7</sup>
$r_{ct}$	Rate of detection and isolation of contacts outside household	$0.9 = (1.1 \text{ days})^{-1}$	
$f_a$	Threshold frequency to define a contact as an acquaintance	1/7 days	
$p_{do}$	Probability to drop out from isolation for individuals that are not clinical	0.13	<sup>8</sup>
$l$	Reduction in household transmission during isolation	0.5	
$d_{NI}, d_I$	Duration of isolation for an individual that is not infectious, duration of isolation for an individual that is infectious	10 days, 10 days	<sup>9</sup>

754

755 **Table S4. Model for test-trace-isolation. Parameters and their values for the case of enhanced TTI. Only**  
 756 **values different from the baseline case are reported.**

Parameter	Description	Value
$p_{d,c}$	Probability that a clinical case is detected	1
$p_{d,sc}$	Probability that a subclinical case is detected	0.5
$r_d$	For detected cases, rate of detection, confirmation and beginning of isolation	$0.9 = (1.1 \text{ days})^{-1}$
$p_{ct,HH}$	Probability that household contacts of an index case are identified and decide to isolate	1
$p_{ct,A}$	Probability that acquaintances of an index case are identified and decide to isolate	0.24
$p_{ct,Oth}$	Probability that the contacts of a detected case outside household are compliant to isolation	0.024

$p_{do}$	Probability to drop out from isolation for individuals that are not clinical	0
----------	--	---

757

## 758 Vaccination strategies

759 We provide here in the following the parameters values for the vaccination strategies detailed  
760 in the Methods section of the main paper.

761 **Table S5. Vaccine administering. Parameters and their baseline values.**

Parameter	Description	Baseline values (other explored values)	Source
$a_{th,v}$	Minimum age for vaccination	18 years	
$P_V^a$	Probability an individual is willing to vaccinate	90% for 65+ 66% for <65	10
$n_{cl}$	For reactive vaccination, cluster size for triggering reactive vaccination in a workplace	1 (2, 3, 4, 5)	
$T_{cl}$	For reactive vaccination, time window for cluster definition	7 days	
$(r_V)^{-1}$	For reactive vaccination, delay of implementation of the vaccination campaign once the cluster is identified (for workplaces/schools) and a case is identified (for households)	2 days (1 day, 4 days)	
$V_{TOT}$	Maximum number of people vaccinated during one simulation	Unlimited	
$V_{day}$	Maximum number of people vaccinated each day	[85, 511] per 100,000 inhabitants per day for Mass, workplaces/universities, school location  Unlimited for reactive ([85, 511] per 100,000 inhabitants per day)	
$size_{th}$	For WP/U, minimum size of a workplace that implement vaccination	20	

762

## 763 **Details on the epidemic simulations**

764 A schematic representation of the main program and of the simulation code and of the  
765 algorithm used for a single stochastic realisation are shown in Figure S1 and S2, respectively.  
766 Simulations are discrete-time and stochastic. At each time step, corresponding to one day,  
767 three processes occur (Figure S2):

768 *vacciantionStep*: vaccines are administered according to the strategy or the strategies'  
769 combination.


770 *testingStep*: cases are detected and isolated; contacts (within and outside household) are  
771 identified and isolated; isolated individuals get out from isolation.

772 *transmissionStep*: infectious status of nodes is updated. This includes transmission, recovery  
773 and transition through the different stages of the infection (e.g. from exposed to pre-  
774 symptomatic, from pre-symptomatic to symptomatic)

775 A single-run simulation is executed with no modelled intervention, until the desired immunity  
776 level is reached. This guarantees that immune individuals are realistically clustered on the  
777 network. We added some noise, by reshuffling the immune/susceptible status of 30% of the  
778 nodes to account for travelling, infection reintroduction from other locations and large  
779 gathering with consequent super-spreading not accounted for by the model. In Figure 2 and 3  
780 of the main paper, all processes (transmission, TTI, vaccination) are simulated from the  
781 beginning of the simulation. In the scenario with virus re-introduction (Figure 4), TTI and mass  
782 vaccination are modelled from the beginning. TTI is enhanced from the detection of the first  
783 case. Reactive vaccination starts after the detection of the first  $n_{RV}$  cases, with  $n_{RV} = 1,5,10$   
784 explored.


785 We vary COVID-19 transmission potential by tuning the daily transmission rate per contact  $\beta$ .  
786 The reproductive number  $R$  is computed numerically as the average number of infections  
787 each infected individual generates throughout its infectious period at the beginning of the  
788 simulation. We tune  $\beta$  to have the desired  $R$  value (1.2 for the analysis in the main text) for  
789 the reference scenario - i.e. with only vaccination at the start. We then compare different  
790 vaccination strategies at the same value of transmissibility  $\beta$ .

791



792

793 Figure S1: Algorithm of the main program. (drawn with code2flow.com)



794

795 Figure S2: Algorithm for one stochastic realisation. (drawn with code2flow.com)

796


## 797 Additional Results

### 798 Comparison between reactive and non-reactive vaccination strategies: 799 sensitivity analysis

800 We compare here reactive vaccination with non-reactive vaccination strategies under a  
801 variety of epidemic scenarios.

802 The impact of reactive vaccination and its demand in terms of vaccine doses varies  
803 depending on the incidence level. Figure S3 compares reactive and workplaces/universities  
804 vaccination in scenarios with variable initial incidence. As initial incidence increases the  
805 reduction in the attack rate due to workplaces/universities vaccination diminishes, while the  
806 one due to reactive vaccination slightly increases. Therefore, the advantage of the reactive  
807 vaccination compared with the other strategy increases. This is explained by the dynamic  
808 adaptation of reactive vaccination to the epidemic situation: the higher the incidence is, the  
809 more vaccines are deployed.

810




811

812 Figure S3 Attack rate (AR) relative reduction (RR) after two months according to the initial incidence for reactive  
813 and workplaces/universities vaccination with 200 and 500 new vaccinated daily. The size of the points is  
814 proportional to the average daily vaccination rate during the period.

815 Figure S4 shows how the relative reduction of the attack rate after two months changes with  
816 transmission, immunity level of the population, fraction of adults initially vaccinated, reduction  
817 in contacts due to social distancing, vaccine efficacy and time needed for the vaccine to  
818 become effective. Here we consider the high incidence scenario (Figure 2A-C of the main  
819 paper) and we compare mass and reactive strategies assuming the same vaccine uptake.  
820 Increasing the transmissibility (panel A) has no significant effect on the efficacy of vaccination  
821 for all strategies considered. Panel B and C show that decreasing the initial proportion of  
822 susceptible, due to increasing either natural immunity or initial vaccination coverage, reduces  
823 the impact of all vaccination strategies. In particular, reactive vaccination has a limited effect  
824 when the initial vaccination coverage is high, as the number of people remaining to vaccinate is  
825 limited. In panel D we explore the impact of teleworking and reduction in community contact  
826 by comparing the baseline scenario with a scenario with no restrictions. Impact of non-

827 reactive vaccination strategies remains almost unaltered. However, reactive vaccination  
 828 becomes more effective when no restriction is in place. This is likely due to the enhanced role  
 829 of workplaces as a setting of transmission when no teleworking is in place, thus bringing to an  
 830 increased benefit of reactive vaccination targeting this setting. In panel E, we explore a  
 831 different hypothesis regarding the effect of vaccination assuming more time for the vaccine  
 832 protection to mount after inoculation. Specifically, we use the parametrisation of <sup>11</sup>, with  $r_{S1} =$   
 833  $0.54$ ,  $r_{S2} = 0.08$  and  $v_1 = v_2 = (14 \text{ days})^{-1}$ . As expected, this change reduces the impact of  
 834 the vaccination campaign. Still, reactive vaccination outperforms mass vaccination at an  
 835 equal number of first-dose vaccination. This result remains valid also when assuming a 30%  
 836 reduction in the vaccine effectiveness in susceptibility with respect to baseline values (panel  
 837 F).



838  
 839 Figure S4. Attack rate (AR) relative reduction (RR) after two months. RR is computed with respect to the reference  
 840 scenario where only initial vaccination is in place. We consider the high incidence scenario, with initial incidence of  
 841 clinical cases 160 per 100,000 inhabitants, and we compare the reactive vaccination (points) with the mass  
 842 vaccination, with 85, 255 and 426 vaccines per 100 000 inhabitants per day (bars). Explored parameters are: the  
 843 reproduction number (A); initial immunity level (B); initial vaccination coverage among 18-60 y.o. People (C);  
 844 presence/absence of teleworking and contact restriction in the community (D); time needed for the vaccine to

845 become effective (E), vaccine efficacy in susceptibility (F). Except when otherwise indicated, parameters are the  
846 same as in Figure 2A of the main text.

847

848 **Comparison between reactive and non-reactive vaccination strategies:**  
849 **additional epidemic outcomes**

850 Based on the estimated incidence of clinical cases per day provided by the transmission  
851 model, we infer outcomes related to hospital, namely hospital and intensive care unit (ICU)  
852 entries, beds in ICU ward, and deaths. We use age-dependent hospital admissions (ICU and  
853 non-ICU) risks estimated by <sup>12,13</sup> and ICU admission risks for hospitalised patients based on  
854 SI-VIC extract <sup>14</sup>. Hospital admissions risks were adjusted to apply only to clinical cases <sup>15</sup>  
855 and to account for vaccine efficacy for hospitalisation for no vaccination, after one week from  
856 vaccine inoculation, and after two weeks from vaccine inoculation <sup>11</sup>. Patients who were  
857 hospitalised entered the hospital on average 7 days (sd = 3.9 days – Gamma distribution)  
858 after the beginning of the infectious phase <sup>16</sup>. Those who were admitted in ICU enter this unit  
859 with a mean delay of 1.69 days (assuming an exponential distribution) <sup>14</sup>. To estimate the  
860 number of occupied beds, we use age-specific mean durations of stay and their  
861 corresponding standard deviations in ICU calculated on all the hospitalised cases in the first 9  
862 months of the French epidemic (March-November 2020)<sup>14</sup>. We assume that the standard  
863 deviations of ICU lengths of stay were equal to the corresponding mean and do not consider  
864 post-ICU care in the estimation of occupied beds. We estimate the number of deaths using  
865 hospital and ICU death risks of hospitalised infected persons <sup>14</sup>. Deaths are delayed in time  
866 using the mean delays and standard deviations from hospital or ICU admission to death <sup>14</sup>. All  
867 lengths of stay are supposed to follow a Gamma distribution. Parameters and their values are  
868 summarised in Tables S6 and S7.

869 We also estimate the number of life years and quality-adjusted life years (QALY) lost for each  
870 death using life-tables provided by ‘French National Institute of Statistics and Economic  
871 Studies’ (INSEE) for 2012-2016 <sup>17</sup> and utility measures of each age-group in France <sup>18</sup>.

872 **Table S6. Risks of hospitalisation according to vaccination status, ICU admission and death in general**  
873 **ward and ICU**

---

Age Group	Hospitalisation risk for no-vaccination	Hospitalisation risk for half vaccination (1 dose)	Hospitalisation risk for full vaccination	ICU admission risk	Death risk in general ward	Death risk in ICU
-----------	---	--	---	--------------------	----------------------------	-------------------

---

	n (2 doses)					
0-9	0,0098	0,0059	0,0211	0,159	0,006	0,078
10-19	0,0054	0,0033	0,0117	0,159	0,006	0,078
20-29	0,0144	0,0087	0,0313	0,159	0,006	0,078
30-39	0,0176	0,0106	0,0381	0,159	0,006	0,078
40-49	0,0245	0,0148	0,0531	0,219	0,016	0,103
50-59	0,0673	0,0407	0,1459	0,270	0,030	0,175
60-69	0,0937	0,0566	0,2029	0,299	0,064	0,268
70-79	0,2029	0,1227	0,4396	0,235	0,140	0,366
79+	0,3768	0,2278	0,8164	0,053	0,308	0,468

874

875 **Table S7. Delays from hospitalisation admission in general ward to death or hospital discharge and delays**  
 876 **from ICU admission to ICU discharge or death.**

Age Group	Mean los in general ward (sd)	Mean los in general ward for dying people (sd)	Mean los in ICU (sd)	Mean los in ICU for dying people (sd)
0-9	6,4 (6,8)	10,6 (12,3)	12,7 (12,7)	22,3 (22,3)
10-19	6,4 (6,8)	10,6 (12,3)	12,7 (12,7)	22,3 (22,3)


20-29	6,4 (6,8)	10,6 (12,3)	12,7 (12,7)	22,3 (22,3)
30-39	6,4 (6,8)	10,6 (12,3)	12,7 (12,7)	22,3 (22,3)
40-49	6,4 (6,8)	10,6 (12,3)	12,7 (12,7)	22,3 (22,3)
50-59	6,4 (6,8)	10,6 (12,3)	12,7 (12,7)	22,3 (22,3)
60-69	9,3 (9,1)	10,6 (12,3)	16,7 (16,7)	20,8 (20,8)
70-79	11,7 (11,4)	10,6 (12,3)	17,5 (17,5)	18,9 (18,9)
79+	15 (13,8)	10,6 (12,3)	13,6 (13,6)	10,6 (10,6)

---

877 Los: Length of stay. Sd = Standard deviation.

878 Figure S5 shows the relative reductions in the number of hospitalisations, deaths, ICU  
879 entries, life-year lost, quality-adjusted life-year lost and ICU bed occupancy at the peak,  
880 comparing each vaccination scenario with the reference scenario - i.e. vaccination only at the  
881 start. We consider here the high incidence scenario and vaccination strategies are compared  
882 at the same vaccine uptake, analogously to Figure 2A of the main paper. The six indicators  
883 show a behaviour similar to incidence. Overall reduction values are smaller. This is expected,  
884 since a large proportion of elderly are already vaccinated at the start, and the compared  
885 vaccination strategies target a population that is less at risk of severe infection. Still all  
886 indicators show the same qualitative behaviour, with reactive vaccination outperforming the  
887 non-reactive vaccination strategies at equal number of first-dose vaccination.

888



889


890 Figure S5. A, B, C, D, E Relative reduction (RR) in the cumulative incidence of hospitalisations, intensive care unit  
 891 (ICU) entries, deaths, life years (LY) lost and quality-adjusted life years (QALY) lost over the first two months for all  
 892 strategies as a function of the vaccination rhythm. F Relative reduction (RR) in occupied ICU beds at the peak  
 893 over the first two months for all strategies as a function of the average daily number of new vaccinated for the high  
 894 incidence scenario. In all cases we assumed the following parameters:  $R=1.2$ ; Initial immunity 26%; vaccinated at  
 895 the beginning are 81% and 13% of 60+ and <60, respectively; teleworking 20% and reduction in contacts in the  
 896 community 30%; initial incidence 160 per 100,000 inhabitants.

897

## 898 **Combined reactive and mass vaccination for managing sustained COVID-19** 899 **spread: additional results**

900 In Figure S6 we show the incidence curve corresponding to the scenarios analysed in Figure  
 901 3A of the main paper. Mass and combined vaccination with the three different vaccination  
 902 paces are compared.

903



904


905 Figure S6 Incidence of clinical cases for mass and combined vaccination strategies for three different vaccination  
906 paces. Scenarios are the same as the ones plotted in Figure 3A. We assumed the following parameters: initial  
907 incidence of clinical cases 160 per 100 000 inhabitants;  $R=1.2$ ; Initial immunity 26%; vaccinated at the beginning  
908 are 81% and 13% of 60+ and <60, respectively; teleworking 20% and reduction in contacts in the community 30%.  
909 Values are means over 2000 stochastic simulations, error bars are not displayed for the sake of visualisation.

910

## 911 **Combined reactive and mass vaccination for managing a COVID-19 flare-up:** 912 **additional results**

913 In Figure S7 we show the incidence curve corresponding to the scenarios analysed in Figure  
914 4 of the main paper. Mass and combined vaccination with the different vaccination scenarios  
915 considered are compared.

916



917

918 Figure S7 Incidence of clinical cases for mass and combined vaccination strategies for the scenarios analysed in  
919 Figure 4 of the main paper. Left: scenario with enhanced TTI. Right: scenario with baseline TTI. In all panels we  
920 assumed the following parameters:  $R=1.2$ ; Initial immunity 26%; 81% and 33% of 60+ and <60 already vaccinated  
921 at the beginning, respectively; no reduction in contacts due to social distancing and teleworking. We assume a  
922 flare-up of cases with 3 cases initially introduced in the population.

923

## 924 References

- 925 1. López, J. A. M. *et al.* Anatomy of digital contact tracing: role of age, transmission setting,  
926 adoption and case detection. *medRxiv* 2020.07.22.20158352 (2020)  
927 doi:10.1101/2020.07.22.20158352.
- 928 2. Li, Q. *et al.* Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected  
929 Pneumonia. *New England Journal of Medicine* **0**, null (2020).
- 930 3. He, X. *et al.* Temporal dynamics in viral shedding and transmissibility of COVID-19.  
931 *Nature Medicine* 1–4 (2020) doi:10.1038/s41591-020-0869-5.
- 932 4. Di Domenico, L., Pullano, G., Sabbatini, C. E., Boëlle, P.-Y. & Colizza, V. Impact of  
933 lockdown on COVID-19 epidemic in Île-de-France and possible exit strategies. *BMC*  
934 *Medicine* **18**, 240 (2020).
- 935 5. Polack, F. P. *et al.* Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *New*

- 936 *England Journal of Medicine* **383**, 2603–2615 (2020).
- 937 6. Baden, L. R. *et al.* Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *New*  
938 *England Journal of Medicine* **384**, 403–416 (2021).
- 939 7. SPF. COVID-19 : point épidémiologique du 6 mai 2021.  
940 [https://www.santepubliquefrance.fr/maladies-et-traumatismes/maladies-et-infections-](https://www.santepubliquefrance.fr/maladies-et-traumatismes/maladies-et-infections-respiratoires/infection-a-coronavirus/documents/bulletin-national/covid-19-point-epidemiologique-du-6-mai-2021)  
941 [respiratoires/infection-a-coronavirus/documents/bulletin-national/covid-19-point-](https://www.santepubliquefrance.fr/maladies-et-traumatismes/maladies-et-infections-respiratoires/infection-a-coronavirus/documents/bulletin-national/covid-19-point-epidemiologique-du-6-mai-2021)  
942 [epidemiologique-du-6-mai-2021](https://www.santepubliquefrance.fr/maladies-et-traumatismes/maladies-et-infections-respiratoires/infection-a-coronavirus/documents/bulletin-national/covid-19-point-epidemiologique-du-6-mai-2021).
- 943 8. Smith, L. E. *et al.* Adherence to the test, trace and isolate system: results from a time  
944 series of 21 nationally representative surveys in the UK (the COVID-19 Rapid Survey of  
945 Adherence to Interventions and Responses [CORSAIR] study). *medRxiv* (2020)  
946 doi:10.1101/2020.09.15.20191957.
- 947 9. Info Coronavirus COVID-19 - Tester - Alerter - Protéger. *Gouvernement.fr*  
948 <https://www.gouvernement.fr/info-coronavirus/tests-et-depistage>.
- 949 10. CoviPrev : une enquête pour suivre l'évolution des comportements et de la santé  
950 mentale pendant l'épidémie de COVID-19. [https://www.santepubliquefrance.fr/etudes-et-](https://www.santepubliquefrance.fr/etudes-et-enquetes/coviprev-une-enquete-pour-suivre-l-evolution-des-comportements-et-de-la-sante-mentale-pendant-l-epidemie-de-covid-19)  
951 [enquetes/coviprev-une-enquête-pour-suivre-l'évolution-des-comportements-et-de-la-](https://www.santepubliquefrance.fr/etudes-et-enquetes/coviprev-une-enquete-pour-suivre-l-evolution-des-comportements-et-de-la-sante-mentale-pendant-l-epidemie-de-covid-19)  
952 [sante-mentale-pendant-l-epidemie-de-covid-19](https://www.santepubliquefrance.fr/etudes-et-enquetes/coviprev-une-enquete-pour-suivre-l-evolution-des-comportements-et-de-la-sante-mentale-pendant-l-epidemie-de-covid-19).
- 953 11. Dagan, N. *et al.* BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass  
954 Vaccination Setting. *New England Journal of Medicine* (2021)  
955 doi:10.1056/NEJMoa2101765.
- 956 12. Kiem, C. T. *et al.* Short and medium-term challenges for COVID-19 vaccination: from  
957 prioritisation to the relaxation of measures. (2021).
- 958 13. Lapidus, N. *et al.* Do not neglect SARS-CoV-2 hospitalization and fatality risks in the  
959 middle-aged adult population. *Infectious Diseases Now* **51**, 380–382 (2021).

- 960 14. Lefrancq, N. *et al.* Evolution of outcomes for patients hospitalised during the first 9  
961 months of the SARS-CoV-2 pandemic in France: A retrospective national surveillance  
962 data analysis. *The Lancet Regional Health – Europe* **5**, (2021).
- 963 15. Davies, N. G. *et al.* Age-dependent effects in the transmission and control of COVID-  
964 19 epidemics. *Nature Medicine* 1–7 (2020) doi:10.1038/s41591-020-0962-9.
- 965 16. Salje, H. *et al.* Estimating the burden of SARS-CoV-2 in France. *Science* (2020)  
966 doi:10.1126/science.abc3517.
- 967 17. Tables de mortalité par sexe, âge et niveau de vie – Tables de mortalité par niveau  
968 de vie | Insee. <https://www.insee.fr/fr/statistiques/3311422?sommaire=3311425>.
- 969 18. Chevalier, J. & de Pouvourville, G. Valuing EQ-5D using time trade-off in France. *Eur*  
970 *J Health Econ* **14**, 57–66 (2013).
- 971
- 972